Iovance updates corporate presentation; FY24 product revenue guidance $160-165M, Q2 revenue $31.1M

IOVANCE BIOTHERAPEUTICS, INC.

FY2024 product revenue guidance of $160-165 million; Q2 2024 net product revenue $31.1 million.
Cash and investments ~$450 million as of July 24, 2024, after ~$200M ATM equity raise in Q2-Q3 2024.
51 Authorized Treatment Centers as of Aug 8, 2024; >225M patient lives covered; >55 patients treated.
Pipeline: TILVANCE-301 Phase 3 frontline melanoma enrolling; IOV-LUN-202 NSCLC registrational data expected 2025.
IOV-END-201 Phase 2 proof-of-concept trial in endometrial cancer initiated; IOV-4001 PD-1 inactivated TIL in Phase 1/2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.